Welcome to our dedicated page for Cannapharmarx news (Ticker: CPMD), a resource for investors and traders seeking the latest updates and insights on Cannapharmarx stock.
CannaPharmaRX, Inc. reports developments in cannabis cultivation and international export operations. The company operates cannabis production activities in Alberta and has described shipments, purchase orders, harvest activity and distribution relationships tied to medical cannabis markets including Israel and Germany.
Recurring updates for CPMD include facility utilization, cannabis strain development, product quality and THC-related pricing, inventory preparation, export licensing, quarterly financial results and balance-sheet initiatives. Company news also covers Canadian regulatory matters, including continuous-disclosure issues with the British Columbia Securities Commission.
CannaPharmaRx (CPMD) announced a 24-month Supply Agreement with Israeli firm Y.S.A Holdings. Under this deal, CannaPharmaRx will cultivate cannabis in Canada and supply a minimum of 400kg annually to YSA for sales in Israel and Morocco, with potential revenues ranging from $6 million to $15 million per year. Deliveries are expected to start in Q3, with purchase orders occurring up to four times a year. This agreement is part of CannaPharmaRx's strategy to build an international brand featuring up to 15 cannabis strains from its exclusive inventory.
Summary not available.
CannaPharmaRx (OTC PINK:CPMD) has signed a letter of intent to acquire LTB Management LLC, an e-commerce platform that enhances online sales. The deal is expected to close in February 2023. LTB's revenues were approximately $3 million in 2022 and are projected to exceed $5 million in 2023 as new products, including cannabis, are introduced. This acquisition is aimed at boosting CannaPharmaRx's sales in Israel and Europe and will diversify its revenue streams, targeting an annual cannabis sales run rate of nearly $30 million. The platform will also enable additional payment options including e-wallets and cryptocurrencies.
CannaPharmaRx, Inc. (OTC PINK:CPMD) announced on February 1, 2023, that its Board of Directors is reviewing actions to address unusual trading activity in its stock. The company suspects manipulative practices, including naked short selling, have artificially depressed its stock price. CannaPharmaRx plans to establish a task force and may consult third-party experts to investigate this issue. CEO Dominic Colvin emphasized the importance of protecting shareholder value and maintaining stock integrity. The company aims to enhance its cannabis production facilities and is in discussions for potential acquisitions.
CannaPharmaRx, Inc. (OTC PINK:CPMD) reported substantial progress in 2022, setting the stage for significant revenue growth in 2023. The company finalized a long-term lease for its Alberta facility, acquired essential cannabis strains, and secured necessary licenses from Health Canada and the CRA. A noteworthy offtake agreement was established with Spring Medical Group, potentially generating up to $12 million. Looking ahead, CannaPharmaRx plans to execute non-dilutive funding, complete key acquisitions, and achieve an annual run rate nearing $30 million while aiming for operational profitability and positive cash flow in the latter half of 2023.
CannaPharmaRx, Inc. (OTC PINK:CPMD) announced it has received its CRA license, allowing it to commence cannabis production and sales in Canada. With licenses from both the CRA and Health Canada secured, the company is set to begin growing cannabis at its facility in Cremona. CannaPharmaRx anticipates its first harvest within the current quarter, projecting annual revenues exceeding $30 million. Additionally, a multi-million-dollar offtake agreement is in negotiation, positioning the company for rapid revenue expansion in the cannabis market.
CannaPharmaRx, Inc. (CPMD) has received a cultivation license from Health Canada, enabling it to legally grow cannabis and sell to licensed producers across Canada. This license, crucial for large-scale production, is expected to facilitate the company's first harvest and sales by Q1 2023, projecting estimated revenues of $30 million over the next year. CEO Nick Colvin highlighted the completion of their Cremona facility and a lucrative offtake agreement as pivotal steps in entering the cannabis market, aiming for rapid revenue growth within the next twelve months.
CannaPharmaRx has received a cultivation license from Health Canada, enabling the company to legally grow and sell cannabis in Canada. This license is crucial for CannaPharmaRx as it prepares to complete its first harvest and commence sales in Q1 2023, with projected revenues of $30 million over 12 months. The company is finalizing preparations at its facility in Cremona and has secured a lucrative offtake agreement. CannaPharmaRx aims to establish itself as a leader in high-quality, low-cost cannabis production.
CannaPharmaRx (OTC PINK:CPMD) has secured new genetic strains of cannabis, submitted to Health Canada, enabling sales to licensed producers. This declaration, part of the standard cultivation license, allows for growing over 200 strains. The genetics are sourced from a top master grower in Canada. The company aims to start harvesting in the first quarter, with plans to distribute heavily demanded products shortly thereafter. CEO Nick Colvin emphasized the focus on acquiring high-quality genetics to meet market demands.
CannaPharmaRx, Inc. (OTC PINK:CPMD) has filed its response to Health Canada on August 31, which is anticipated to be a crucial step towards obtaining a cultivation license. This license is essential for large-scale cannabis production and will allow CPMD to grow and sell cannabis wholesale to other license holders. Following a recent multi-million dollar offtake agreement, the company expects to finalize its cultivation license this month, aiming to commence operations in Q4 2022.